| Title |
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma
|
|---|---|
| Published in |
Lung Cancer: Targets and Therapy, June 2017
|
| DOI | 10.2147/lctt.s135802 |
| Pubmed ID | |
| Authors |
Muhammad Omer Jamil, Mary S Jerome, Deborah Miley, Katri S Selander, Francisco Robert |
| Abstract |
Malignant pleural mesothelioma (MPM) is a rare malignancy with a dismal median survival of <12 months with current therapy. Single and combination chemotherapy regimens have shown only modest clinical benefit. In preclinical studies, nitrogen-containing bisphosphonates (zoledronic acid) inhibit growth of mesothelioma cells by different mechanisms: inhibition of mevalonate pathway, inhibition of angiogenesis, activation of apoptosis through caspase activation, and alteration in activity of matrix metalloproteinases, thereby affecting invasiveness of cancer cells. We investigated the role of zoledronic acid in a pilot, single-arm trial of MPM patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 who had progressed on prior treatments or had not received systemic therapy due to poor PS. Primary end point was composite response rate by modified response evaluation criteria in solid tumors and/or metabolic response by 2-deoxy-2-[fluorine-18]fluoro-d-glucose ((18)F-FDG) positron emission tomography criteria. Secondary end points were progression-free survival (PFS) and overall survival (OS). Exploratory end points include the effect of zoledronic acid therapy on vascular endothelial growth factor (VEGF), basic fibroblast growth factor, interleukin 8, transforming growth factor beta, mesothelin, and osteopontin levels. Eight male patients (median age of 62 years) with the following clinical characteristics were treated; ECOG PS was 0-2, 75% with epithelioid type, and 62% had prior chemotherapy Overall composite response rate was 12.5% and the clinical benefit rate (response + stable disease) was 37.5%. Median PFS was 2 months (0.5-21 months) and median OS was 7 months (0.8-28 months). No treatment-related toxicities were observed. Lower VEGF levels were predictive of favorable response and mesothelin levels correlated with disease course. Zoledronic acid shows modest clinical activity without significant toxicity in patients with advanced MPM. |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 23% |
| Student > Ph. D. Student | 2 | 15% |
| Student > Master | 2 | 15% |
| Student > Bachelor | 1 | 8% |
| Student > Postgraduate | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 4 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 38% |
| Biochemistry, Genetics and Molecular Biology | 1 | 8% |
| Veterinary Science and Veterinary Medicine | 1 | 8% |
| Immunology and Microbiology | 1 | 8% |
| Agricultural and Biological Sciences | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 4 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 419. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2017.
All research outputs
#69,996
of 25,604,262 outputs
Outputs from Lung Cancer: Targets and Therapy
#1
of 128 outputs
Outputs of similar age
#1,549
of 331,069 outputs
Outputs of similar age from Lung Cancer: Targets and Therapy
#1
of 6 outputs
Altmetric has tracked 25,604,262 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 128 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,069 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them